Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 22194397)

1.

Nuclear JAK2.

Dawson MA, Bannister AJ, Saunders L, Wahab OA, Liu F, Nimer SD, Levine RL, Göttgens B, Kouzarides T, Green AR.

Blood. 2011 Dec 22;118(26):6987-8. doi: 10.1182/blood-2011-10-385278. No abstract available.

2.

Confocal imaging studies cast doubt on nuclear localization of JAK2V617F.

Girodon F, Steinkamp MP, Cleyrat C, Hermouet S, Wilson BS.

Blood. 2011 Sep 1;118(9):2633-4. doi: 10.1182/blood-2011-02-336479. No abstract available.

3.

Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals.

Wang YL, Lee JW, Kui JS, Chadburn A, Cross NC, Knowles DM, Coleman M.

Acta Haematol. 2007;118(4):209-14. Epub 2007 Nov 21.

PMID:
18032883
4.

Detecting the JAK2 V617F mutation in fresh and 'historic' blood and bone marrow.

Gattenlohner S, Peter C, Bonengel M, Einsele H, Bargou R, Müller-Hermelink HK, Marx A.

Leukemia. 2007 Jul;21(7):1599-602. Epub 2007 Apr 26. No abstract available.

PMID:
17460708
5.

The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient.

Zhang SJ, Li JY, Li WD, Song JH, Xu W, Qiu HX.

Int J Lab Hematol. 2007 Feb;29(1):71-2. No abstract available.

PMID:
17224012
6.

Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.

Sanz A, Ungureanu D, Pekkala T, Ruijtenbeek R, Touw IP, Hilhorst R, Silvennoinen O.

PLoS One. 2011 Apr 18;6(4):e18522. doi: 10.1371/journal.pone.0018522.

7.

Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.

Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ruiz-Delgado GJ, Rosillo C, Camoriano JK.

Am J Hematol. 2007 May;82(5):400-2.

PMID:
17133423
8.

MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.

Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A.

Haematologica. 2006 Dec;91(12 Suppl):ECR57.

9.

Absence of JH2 domain mutation of the tyrosine kinase JAK2 in renal cell carcinomas.

Zhao J, Moch H.

Acta Oncol. 2008;47(3):474-6. No abstract available.

PMID:
17851851
10.

The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.

Wadleigh M, Gilliland DG.

Curr Hematol Malig Rep. 2006 Jun;1(2):75-80. doi: 10.1007/s11899-006-0026-3. Review.

PMID:
20425335
11.

SUMOylation is a regulator of the translocation of Jak2 between nucleus and cytosol.

Sedek M, Strous GJ.

Biochem J. 2013 Jul 15;453(2):231-9. doi: 10.1042/BJ20121375.

12.

Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity.

Li Z, Xing S, Wang S, Ho WT, Zhao ZJ.

Exp Hematol. 2007 Nov;35(11):1624-32. Epub 2007 Aug 30.

13.

Nuclear localization of functional FGF receptor 1 in human astrocytes suggests a novel mechanism for growth factor action.

Stachowiak MK, Maher PA, Joy A, Mordechai E, Stachowiak EK.

Brain Res Mol Brain Res. 1996 May;38(1):161-5.

PMID:
8737680
15.

A prenatal origin of childhood essential thrombocythaemia.

Langabeer SE, Haslam K, McMahon C.

Br J Haematol. 2013 Dec;163(5):676-8. doi: 10.1111/bjh.12533. Epub 2013 Aug 16. No abstract available.

PMID:
23952300
16.

The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders.

Kiladjian JJ, Casadevall N, Vainchenker W, Fenaux P.

Pathol Biol (Paris). 2007 Mar;55(2):85-7. Epub 2006 Aug 9.

PMID:
16901656
17.

JAK2, the JAK2 V617F mutant and cytokine receptors.

Staerk J, Kallin A, Royer Y, Diaconu CC, Dusa A, Demoulin JB, Vainchenker W, Constantinescu SN.

Pathol Biol (Paris). 2007 Mar;55(2):88-91. Epub 2006 Aug 14. Review.

PMID:
16904848
18.

No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.

Ditschkowski M, Elmaagacli AH, Trenschel R, Steckel NK, Koldehoff M, Beelen DW.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1350-1. No abstract available.

19.

Accuracy of leukocyte alkaline phosphatase score to predict JAK2 V617F mutation.

Basquiera AL, Fassetta F, Soria N, Barral JM, Ricchi B, García JJ.

Haematologica. 2007 May;92(5):704-5.

20.

Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders.

Shen YM, Chao HY, Zhang R, Feng YF, Cen JN, Yao L, Shen HJ, Zhu ZL, Xue YQ.

J Int Med Res. 2009 Jan-Feb;37(1):37-46.

PMID:
19215672
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk